The Experts below are selected from a list of 3255 Experts worldwide ranked by ideXlab platform
Mingcheh Liu - One of the best experts on this subject based on the ideXlab platform.
-
sulfation of Ritodrine by the human cytosolic sulfotransferases sults effects of sult1a3 genetic polymorphism
European Journal of Pharmacology, 2015Co-Authors: Ying Hui, Mingcheh LiuAbstract:Previous studies have demonstrated the metabolism of Ritodrine through sulfation. The current study was designed to identify the human SULTs that are capable of sulfating Ritodrine and to investigate how genetic polymorphism of the major Ritodrine-sulfating SULT, SULT1A3, may affect its sulfating activity. A systematic analysis revealed that of the 13 known human SULTs, SULT1A1, SULT1A3, and SULT1C4, were capable of mediating the sulfation of Ritodrine, with SULT1A3 displaying the strongest sulfating activity. Effects of genetic polymorphism on the sulfating activity of SULT1A3 were examined. By employing site-directed mutagenesis, 4 SULT1A3 allozymes were generated, expressed, and purified. Purified SULT1A3 allozymes were shown to exhibit differential sulfating activity toward Ritodrine. Kinetic studies further demonstrated differential substrate affinity and catalytic efficiency among the SULT1A3 allozymes. Collectively, these results provided useful information concerning the differential metabolism of Ritodrine through sulfation in different individuals.
Kohta Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
association between total dose of Ritodrine hydrochloride and pulmonary oedema in twin pregnancy a retrospective cohort study in japan
BMJ Open, 2017Co-Authors: Satoshi Shinohara, Rei Sunami, Yuzo Uchida, Shuji Hirata, Kohta SuzukiAbstract:Objective Pulmonary oedema is recognised as a severe side effect of Ritodrine hydrochloride. Recently, the number of twin pregnancies has been increasing. Few studies have reported the association between total dose of Ritodrine hydrochloride prior to delivery and pulmonary oedema in twin pregnancy. We aimed to examine this association and determine the optimal cut-off threshold of total Ritodrine hydrochloride dose to predict the incidence of pulmonary oedema in twin pregnancy based on obstetric records. Design Retrospective cohort study. Setting Yamanashi Prefectural Central Hospital, Japan. Participants Two hundred and twenty-six women with twin pregnancy who delivered at Yamanashi Prefectural Central Hospital between September 2009 and November 2016. Methods The obstetric records of the participants were analysed. We defined 1 unit of Ritodrine hydrochloride as 72 mg per 24 hours continuous transfusion at 50 µg/min to calculate the dose of Ritodrine used for tocolysis. Outcome measures Multivariable logistic regression analysis was performed to examine the association between total dose of Ritodrine hydrochloride used for threatened preterm labour and pulmonary oedema, while controlling for potential confounding factors. Then, a receiver–operating characteristic curve was used to determine the optimal cut-off of total Ritodrine dose to predict pulmonary oedema incidence. Results Mean maternal age was 32 (range, 18–46) years; 143 participants were nulliparous (63.3%), 109 had (48.2%) term deliveries and 194 (85.8%) had caesarean deliveries. The overall incidence of pulmonary oedema was 13.7% (31/226). Multivariable analysis showed that the total dose of Ritodrine was significantly associated with pulmonary oedema (adjusted OR 1.02; 95% CI 1.004 to 1.03). The best cut-off point to predict the incidence of pulmonary oedema was 26 units (1872 mg) (sensitivity, 61.3%; specificity, 87.8%). Conclusion Our results suggest that consideration of the total dose of Ritodrine hydrochloride is helpful in the management of patients with threatened preterm labour in twin pregnancy.
Takeo Nakayama - One of the best experts on this subject based on the ideXlab platform.
-
effectiveness and safety of Ritodrine hydrochloride for the treatment of preterm labour a systematic review
Pharmacoepidemiology and Drug Safety, 2006Co-Authors: Yukari Yaju, Takeo NakayamaAbstract:Purpose To analyse the available data on the effectiveness and safety of Ritodrine hydrochloride in delaying delivery and in decreasing the incidence of preterm birth. Methods Systematic review of randomised controlled trials (RCTs) that compared the effectiveness and safety of Ritodrine hydrochloride with a placebo or with no treatment. Main outcome measures were relative risks (RRs) for perinatal mortality, neonatal respiratory distress syndrome (RDS), delivery within 48 hours or 7 days, preterm birth before 37 weeks gestation and low birth weight. We searched computerised databases (MEDLINE, CENTRAL, Ichushi Web) from their inception to October 2004, and searched the references of eligible trials. Results Seventeen RCTs were included and meta-analysis was conducted. Pooled RRs relative to placebo for delivery within 48 hours or 7 days for parenteral Ritodrine hydrochloride were 0.74 (95%CI (confidential interval): 0.56, 0.97), 0.85 (95%CI: 0.74, 0.97). There was no significant decrease in perinatal mortality, the proportion of RDS, preterm birth and low birth weight infants. Maternal side-effects significantly increased in patients receiving Ritodrine with respect to those receiving a placebo. Pooled RRs relative to placebo for oral Ritodrine hydrochloride showed no significant decrease in primary and secondary endpoints. Conclusions The effectiveness of parenteral Ritodrine hydrochloride for tocolysis in preterm labour is limited to short-range prolongation of gestation. The effectiveness of maintenance tocolytic therapy with oral Ritodrine hydrochloride was not proved. Copyright © 2006 John Wiley & Sons, Ltd.
Gustaaf A Dekker - One of the best experts on this subject based on the ideXlab platform.
-
hemodynamic and metabolic effects after nifedipine and Ritodrine tocolysis
International Journal of Gynecology & Obstetrics, 2003Co-Authors: D N M Papatsonis, H P Van Geijn, H J Ader, O P Bleker, Gustaaf A DekkerAbstract:Objectives: The purpose of this study is to compare the hemodynamic and metabolic changes after Ritodrine and nifedipine tocolysis. Methods: For an open randomized study, patients with preterm labor (N=185) were allocated to groups to receive Ritodrine intravenously (N=90) or nifedipine orally (N=95). Results: The mean diastolic blood pressure was significantly lower in the Ritodrine group 24 h (65±12 vs. 70±8, P=0.001) and 48 h (65±12 vs. 71±8, P=0.004) after starting tocolysis compared with the nifedipine group. Mean maternal heart rate was significantly higher in the Ritodrine group 24 h (105±17 vs. 86±13, P<0.0001) and 48 h (100±21 vs. 85±12, P<0.0001) after starting tocolysis compared with the nifedipine group. Mean fasting glucose levels were higher (6.68±2.53 vs. 4.93±1.23, P=0.0016), while mean potassium levels were lower (3.52±0.84 vs. 3.81±0.45, P=0.04) in the Ritodrine group 48 h after starting tocolysis compared with the nifedipine group. Conclusions: Use of nifedipine for preterm labor is associated with a lower incidence of adverse hemodynamic and metabolic changes compared with Ritodrine after 24 and 48 h of tocolysis. In our opinion nifedipine is the preferred drug of choice for the treatment of preterm labor.
-
Hemodynamic and metabolic effects after nifedipine and Ritodrine tocolysis.
International Journal of Gynecology & Obstetrics, 2003Co-Authors: D N M Papatsonis, H P Van Geijn, H J Ader, Otto P. Bleker, Gustaaf A DekkerAbstract:Objectives: The purpose of this study is to compare the hemodynamic and metabolic changes after Ritodrine and nifedipine tocolysis. Methods: For an open randomized study, patients with preterm labor (N=185) were allocated to groups to receive Ritodrine intravenously (N=90) or nifedipine orally (N=95). Results: The mean diastolic blood pressure was significantly lower in the Ritodrine group 24 h (65±12 vs. 70±8, P=0.001) and 48 h (65±12 vs. 71±8, P=0.004) after starting tocolysis compared with the nifedipine group. Mean maternal heart rate was significantly higher in the Ritodrine group 24 h (105±17 vs. 86±13, P
-
nifedipine and Ritodrine in the management of preterm labor a randomized multicenter trial
Obstetrics & Gynecology, 1997Co-Authors: D N M Papatsonis, H P Van Geijn, H J Ader, F M Lange, O P Bleker, Gustaaf A DekkerAbstract:Objective: To compare the efficacy of nifedipine with Ritodrine in the management of preterm labor. Methods: One hundred eighty-five singleton pregnancies with preterm labor were assigned randomly to either Ritodrine intravenously (n = 90) or nifedipine orally (n = 95). The principal outcome assessed was delay of delivery. Results: Ritodrine was discontinued in 12 patients because of severe maternal side effects, and their results were excluded from further analysis. More women in the Ritodrine group delivered within 24 hours (22 versus 11, P = .006), within 48 hours (29 versus 21, P = .03), within 1 week (45 versus 36, P = .009), and within 2 weeks (52 versus 43, P = .005) compared with those receiving nifedipine. There were significantly fewer maternal side effects in the nifedipine group. Apgar scores and umbilical artery and vein pHs were similar in both groups. The number of admissions to the neonatal intensive care unit (NICU) in the nifedipine group was significantly lower than in the Ritodrine group (68.4 versus 82.1%, P = .04). Conclusion: Nifedipine in comparison with Ritodrine in the management of preterm labor is significantly associated with a longer postponement of delivery, fewer maternal side effects, and fewer admissions to the NICU.
S Campbell - One of the best experts on this subject based on the ideXlab platform.
-
glyceryl trinitrate and Ritodrine in tocolysis an international multicenter randomized study
Obstetrics & Gynecology, 1999Co-Authors: Christoph Lees, Luana Danti, P Tanzi, Rebecca S. Black, Ian R White, Andrea Lojacono, Catherine Thompson, S CampbellAbstract:Abstract Objective: To compare the efficacy of transdermal glyceryl trinitrate and intravenous (IV) Ritodrine as tocolytics. Methods: Two hundred forty-five women with preterm labor and intact membranes between 24 and 36 weeks' gestation were randomized to transdermal glyceryl trinitrate or intravenous Ritodrine. Treatment was continued until contractions stopped or a maximum of 7 days. Glyceryl trinitrate was administered as a 10- or 20-mg transdermal patch. Intravenous Ritodrine was administered according to nationally available guidelines. The primary outcome was prolongation of gestation expressed as a percentage of the time from entry to 37 weeks. Secondary outcomes were proportion of women who delivered the same day, next day, or within 7 and 14 days of entry, and by 32, 34, and 37 weeks. Analysis was by intention to treat. Results: Twelve women (5%) were lost to follow-up. Glyceryl trinitrate and Ritodrine prolonged gestation by 74% of time to 37 weeks (difference glyceryl trinitrate-Ritodrine 0%; 95% confidence interval (CI) −10%, +10%). There was no significant difference in the proportion of women receiving glyceryl trinitrate or Ritodrine who delivered within the specified days from study entry or weeks of gestation; however, 42 women who received glyceryl trinitrate and 58 women who received Ritodrine delivered by 37 weeks (difference −11%; 95% CI −24%, +2%). No serious maternal side effects were reported for Ritodrine or glyceryl trinitrate. Conclusion: We found no overall difference between glyceryl trinitrate and Ritodrine in the acute tocolysis of preterm labor but a suggested advantage of glyceryl trinitrate over Ritodrine in reducing preterm delivery rate. The maternal side effect profile and treatment discontinuation rates were fewer for glyceryl trinitrate, suggesting it was a safer alternative to Ritodrine.
